- Home
- AXS vs HALO Comparison
AXS vs HALO Comparison
Compare AXS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXS
- HALO
- Stock Information
- Founded
- AXS 2001
- HALO 1998
- Country
- AXS Bermuda
- HALO United States
- Employees
- AXS N/A
- HALO N/A
- Industry
- AXS Property-Casualty Insurers
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXS Finance
- HALO Health Care
- Exchange
- AXS Nasdaq
- HALO Nasdaq
- Market Cap
- AXS 8.1B
- HALO 7.4B
- IPO Year
- AXS N/A
- HALO N/A
- Fundamental
- Price
- AXS $102.54
- HALO $52.02
- Analyst Decision
- AXS Strong Buy
- HALO Buy
- Analyst Count
- AXS 9
- HALO 9
- Target Price
- AXS $107.75
- HALO $63.56
- AVG Volume (30 Days)
- AXS 565.6K
- HALO 3.1M
- Earning Date
- AXS 04-30-2025
- HALO 05-06-2025
- Dividend Yield
- AXS 1.72%
- HALO N/A
- EPS Growth
- AXS 54.31
- HALO 55.40
- EPS
- AXS 10.08
- HALO 3.76
- Revenue
- AXS $6,055,200,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- AXS $4.15
- HALO $24.79
- Revenue Next Year
- AXS $5.74
- HALO $22.65
- P/E Ratio
- AXS $10.14
- HALO $13.83
- Revenue Growth
- AXS 5.79
- HALO 25.64
- 52 Week Low
- AXS $68.02
- HALO $41.28
- 52 Week High
- AXS $101.42
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- AXS 64.39
- HALO 39.78
- Support Level
- AXS $98.40
- HALO $47.50
- Resistance Level
- AXS $102.36
- HALO $69.94
- Average True Range (ATR)
- AXS 2.23
- HALO 3.52
- MACD
- AXS 0.26
- HALO -1.49
- Stochastic Oscillator
- AXS 99.79
- HALO 19.64
About AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.